Medical expert of the article
New publications
Preparations
Agelmin-DARNITSA
Last reviewed: 23.04.2024
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Medication Agelmin-Darnitsa refers to antiparasitic drugs, derivatives of benzimidazole. The drug is produced at the ZAO Darnitsa Pharmaceutical Factory, Kiev.
Indications Agelmin-DARNITSA
Agelmin-Darnitsa is used for anthelmintic treatment of diseases caused by ascarids, trichocephals (withers), pinworms, intestinal ugrices (strongyloids), pork chain (flat helminth), hookworms (roundworms). You can apply the drug for helminthiases of mixed type.
Release form
The medication Agelmin-Darnitsa is made in tableted form with a yellowish-gray hue, with a flattened surface, with a characteristic notch in the center for convenient dosing. Tablets have a weak specific flavor.
Each tablet consists of the active substance mebendazole and additional substances: starch, aerosil, magnesium stearate. Chemical terminology of the preparation 5-Benzoylbenzimidazol-2-yl methyl ester of urea.
Pharmacodynamics
Agelmin-Darnitza is a synthetic antihelminthic drug. Its antiparasitic activity has a wide spectrum of action. With the use of the drug, a disturbance of the energy process in helminths is observed, besides, Agelmin causes degeneration processes in cytoplasmic protein intracellular structures that are part of the cytoskeleton, upsets the absorption of glucose and inhibits the production of ATP in the parasitic organism.
Medication Agelmin-Darnitsa has a high activity in infestations involving intestinal nematodes and other known helminths.
Pharmacokinetics
After using the drug Agelmin-Darnitsa, the active substance is not absorbed into the systemic circulation (about 5-10%). Part of the component found in the blood is converted in the liver into an inactive derivative, with 90% of the substance forming a bond with the plasma proteins. In the body, the distribution of the drug is uneven, there is an accumulation in the fatty layer of the liver.
Excretion of 2% of the drug occurs through the urinary system for two days. The half-life of the active substance is 3-5 hours.
The active component of the drug, which did not enter the systemic circulation, is excreted in the unmodified form with the feces.
Dosing and administration
The drug is consumed inside: the drug form can be swallowed, washed down with liquid, or crushed and mixed with food or juice. During the course of treatment, it is not necessary to observe any special diet or to use a laxative for the early evacuation of the intestine.
The length of the course of therapy and dosage is determined by the doctor.
With symptoms of enterobiasis, one tablet of the drug (100 mg) is usually prescribed once. To repeat reception it is possible in the same dosage after 14-28 days. Treatment should be applied to all members of the family without exception. Children can take ¼ or ½ tablets, the frequency of admission and the duration of the course is determined by a specialist.
Trichocephalus, ankylostomiasis and ascariasis require the administration of 100 mg of the drug twice a day, 3 consecutive days.
Tenidosis and strongyloidiasis require the application of 200 mg of the drug twice a day, 3 days in a row. Children dosage is up to 100 mg per treatment.
After 21 days, it is necessary to undergo a helminthiasis examination and, if the results are positive, a second course of treatment should be carried out.
Use Agelmin-DARNITSA during pregnancy
The drug Agelmin passed all clinical studies that showed that the active ingredient of the drug is capable of exerting an embryotoxic and teratogenic effect, that is, negatively affecting the development of the embryo and the process of pregnancy. Therefore, during the period of gestation (especially in the first trimester), the use of Agelmin-Darnitsa is prohibited. In extremely rare situations, the drug is still prescribed, but the doctor should sensibly evaluate the benefits of taking the medication and the possible negative impact on the fetus.
During breastfeeding, the drug is not treated. If the drug can not be avoided, breastfeeding is temporarily stopped. After the completion of the treatment course, lactation can be restored.
Contraindications
Medication Agelmin-Darnitsa is not used to treat patients with hypersensitivity to the active or any additional substance that is part of the drug.
The drug is not prescribed to patients with severe disorders of liver function, with ulcerative lesions of the intestine, with Crohn's disease (lesion of the gastrointestinal tract of an unknown etiology).
In childhood, Agelmin is allowed to use from 2 years. For younger children, weaker anthelmintic agents are usually used. Sometimes, if the digestion of a baby is significantly impaired by parasites, the drug can be used in children up to 2 years. The drug should be taken under the compulsory supervision of a doctor.
Carefully prescribe Agelmin to a diabetic patient: the active component of the drug can reduce the need for an organism in insulin.
Side effects Agelmin-DARNITSA
Usually patients are well tolerated. Side effects are only rare, but they need to know about:
- a feeling of fatigue, pain in the head, dizziness;
- pain in the projection of the stomach, digestive disorders;
- fever, seizure syndrome.
With the use of large dosages of the drug may develop alopecia, neutropenia, anemia, leukopenia, impaired liver function, urinary excretion of erythrocytes and hyaline cylinders.
Overdose
When using the drug in a dosage much more therapeutic, the patient may experience a digestive disorder. A prolonged overdose can trigger violations of the liver function, neutropenia.
The antidote, which neutralizes the Agelmin-Darnitsa effect, has not been developed.
When there are signs of overdose, it is necessary to cancel the drug and conduct a standard series of activities that are recommended for any drug intoxication. Such activities include the following sequence of actions: rinse the stomach, give the patient a sorbent preparation, conduct symptomatic therapy if necessary.
Interactions with other drugs
It is not recommended to use medication together with alcohol and alcohol-containing medicines. The use of alcoholic beverages and drugs based on alcohol is allowed 24 hours after the end of the drug.
The drug can slow down metabolism and accumulate in the body in small amounts when combined with cimetidine.
The content of the active component in the plasma is reduced by the action of phenytoin and carbamazepine.
The drug lowers the body's need for insulin. For this reason, when combined use of insulin and Agelmin should periodically check the balance of glucose in the blood.
[Storage conditions
The drug is recommended to store in a dry, dark place, protected from free access of children.
Shelf life
Shelf life - up to 2 years.
Attention!
To simplify the perception of information, this instruction for use of the drug "Agelmin-DARNITSA" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.
Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.